The Influence of HIV Infection and Antiretroviral Therapy on the Mitochondrial Membrane Potential of Peripheral Mononuclear Cells

Brinkman K. , ter Hofstede H.J. , Burger D.M. , Smeitink J.A. , Koopmans P.P. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735–1744.

Bauer A.M. , Sternfeld T. , Horster S. Kinetics of lactate metabolism after submaximal ergometric exercise in HIV-infected patients. HIV Med 2004; 5: 371–376.

Brinkman K. , Smeitink J.A. , Romijn J.A. , Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354: 1112–1115.

Shikuma C.M. , Hu N. , Milne C. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 2001; 15: 1801–1809.

Arnaudo E. , Dalakas M. , Shanske S. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337: 508–510.

McComsey G. , Tan D.J. , Lederman M. , Wilson E. , Wong L.J. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 2002; 16: 513–518.

Casula M. , Weverling G.J. , Wit F.W. Mitochondrial DNA and RNA increase in peripheral blood mononuclear cells from HIV-1-infected patients randomized to receive stavudine-containing or stavudine-sparing combination therapy. J Infect Dis 2005; 192: 1794–1800.

McComsey G. , Maa J.F. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy. AIDS Read 2003; 13: 539–542, 559.

Cossarizza A. Tests for mitochondrial function and DNA: potentials and pitfalls. Curr Opin Infect Dis 2003; 16: 5–10.

Macho A. , Castedo M. , Marchetti P. Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood 1995; 86: 2481–2487.

Cossarizza A. , Baccarani-Contri M. , Kalashnikova G. , Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5’,6,6’-tetrachloro-1,1’,3,3’-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun 1993; 197: 40–45.

Cossarizza A. , Mussini C. , Mongiardo N. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS 1997; 11: 19–26.

Cossarizza A. , Mussini C. , Borghi V. Apoptotic features of peripheral blood granulocytes and monocytes during primary, acute HIV infection. Exp Cell Res 1999; 247: 304–311.

Ferraresi R. , Troiano L. , Rossi D. Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach. Mitochondrion 2004; 4: 271–278.

Lugli E. , Troiano L. , Ferraresi R. Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry A 2005; 68: 28–35.

Rottenberg H. , Wu S. Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. Biochim Biophys Acta 1998; 1404: 393–404.

Vayssier-Taussat M. , Kreps S.E. , Adrie C. Mitochondrial membrane potential: a novel biomarker of oxidative environmental stress. Environ Health Perspect 2002; 110: 301–305.

Verhoeven A.J. , Verhaar R. , Gouwerok E.G. , de Korte D. The mitochondrial membrane potential in human platelets: a sensitive parameter for platelet quality. Transfusion 2005; 45: 82–89.

Wan B. , Doumen C. , Duszynski J. Effects of cardiac work on electrical potential gradient across mitochondrial membrane in perfused rat hearts. Am J Physiol 1993; 265: H453–H460.

Buttgereit F. , Burmester G.R. , Brand M.D. Bioenergetics of immune functions: fundamental and therapeutic aspects. Immunol Today 2000; 21: 192–199.

Green D.R. , Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626–629.

Banas B. , Kost B.P. , Goebel F.D. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004; 9: 371–377.

Mathur A. , Hong Y. , Kemp B.K. , Barrientos A.A. , Erusalimsky J.D. Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc Res 2000; 46: 126–138.

Smiley S.T. , Reers M. , Mottola-Hartshorn C. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A 1991; 88: 3671–3675.

Salvioli S. , Ardizzoni A. , Franceschi C. , Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997; 411: 77–82.

Tong V. , Teng X.W. , Chang T.K. , Abbott F.S. Valproic acid II: effects on oxidative stress, mitochondrial membrane potential, and cytotoxicity in glutathione-depleted rat hepatocytes. Toxicol Sci 2005; 86: 436–443.

Risso A. , Braidot E. , Sordano M.C. BMAP-28, an antibiotic peptide of innate immunity, induces cell death through opening of the mitochondrial permeability transition pore. Mol Cell Biol 2002; 22: 1926–1935.

Almeida A. , Almeida J. , Bolanos J.P. , Moncada S. Different responses of astrocytes and neurons to nitric oxide: the role of glycolytically generated ATP in astrocyte protection. Proc Natl Acad Sci U S A 2001; 98: 15294–15299.

Sarkar S. , Kalia V. , Montelaro R.C. Caspase-mediated apoptosis and cell death of rhesus macaque CD4⁺ T-cells due to cryopreservation of peripheral blood mononuclear cells can be rescued by cytokine treatment after thawing. Cryobiology 2003; 47: 44–58.

Polo R. , Martinez S. , Madrigal P. , Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. J Acquir Immune Defic Syndr 2003; 34: 32–36.

Kakuda T.N. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000; 22: 685–708.

de Mendoza C. , de Ronde A. , Smolders K. Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. AIDS Res Hum Retroviruses 2004; 20: 271–273.

Lopez S. , Miro O. , Martinez E. Mitochondrial effects of antiretroviral therapies in asymptomatic patients. Antivir Ther 2004; 9: 47–55.

Cote H.C. , Yip B. , Asselin J.J. Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens. J Infect Dis 2003; 187: 1972–1976.

Martin J.L. , Brown C.E. , Matthews-Davis N. , Reardon J.E. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38: 2743–2749.

Walker U.A. , Setzer B. , Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 2165–2173.

van der Valk M. , Casula M. , Weverlingz G.J. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther 2004; 9: 385–393.

Cossarizza A. , Riva A. , Pinti M. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003; 8: 315–321.

Maagaard A. , Holberg-Petersen M. , Kvittingen E. , Sandvik L. , Bruun J. Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naive patients. HIV Med 2006; 7: 53–58.

Miro O. , Lopez S. , Martinez E. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with anti-retrovirals. Clin Infect Dis 2004; 39: 710–716.

Chiappini F. , Teicher E. , Saffroy R. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157 consecutively recruited untreated or HAART-treated HIV-positive patients. Lab Invest 2004; 84: 908–914.

Miura T. , Goto M. , Hosoya N. Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy. J Med Virol 2003; 70: 497–505.

Montaner J.S. , Cote H.C. , Harris M. Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004; 38 Suppl 2: S73–79.

Hoschele D. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity. Toxicol In Vitro 2006; 20: 535–546.

Cote H.C. , Brumme Z.L. , Craib K.J. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346: 811–820.

Carter V.M. , Hoy J.F. , Bailey M. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med 2001; 2: 174–180.

Carr A. , Emery S. , Law M. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 2003; 361: 726–735.

Nolan D. , Hammond E. , Martin A. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329–1338.

Rabing Christensen E. , Stegger M. , Jensen-Fangel S. , Laursen A.L. , Ostergaard L. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004; 39: 1371–1379.

Lichtenstein K.A. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395–400.